Arcutis Biotherapeutics Inc (ARQT) Income Statement
An income statement shows a company's revenue, expenses, and profit over a reporting period.
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis.
Total Revenue Chart for Arcutis Biotherapeutics Inc
Arcutis Biotherapeutics Inc (ARQT) revenue for FY2025 was USD 376.1M, a 91.3% change from FY2024. Arcutis Biotherapeutics Inc's revenue moved from USD 0.00 in 2017 to USD 376.1M in 2025 over 8 years. Earnings per share moved from USD -4.71 in 2017 to USD -5.66 in 2022.
Total Revenue (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $3.92B
- Implied Share Price
- $31.20
- Enterprise Value
- $2.47B
- Revenue (TTM)
- $463.98M
- EBITDA
- $36.50M
- Profit Margin
- 6.15%
- Trailing P/E
- 141.82
- Forward P/E
- 263.16
- Price/Book (MRQ)
- 18.33
- Price/Sales (TTM)
- 8.45
- EV/EBITDA
- -2.04
- EV/Revenue
- 9.36
- Dividend Yield
- —
- Book Value
- $1.76
- Free Cash Flow (FY2025)
- -$6.31M
- Free Cash Flow Yield
- -0.16%
Snapshot as of 25th October 2026 — not point-in-time controlled, may lag the live market by a few days.